Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
0.6200
-0.5150 (-45.37%)
Oct 7, 2026, 1:46 PM EDT - Market open
Caribou Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10.04 | 11.16 | 9.99 | 34.48 | 13.85 | 9.6 | |
Revenue Growth | 10.02% | 11.66% | -71.01% | 148.91% | 44.31% | -22.35% |
Cost of Revenue | 83.85 | 107.52 | 130.15 | 112.08 | 82.23 | 52.26 |
Gross Profit | -73.82 | -96.36 | -120.16 | -77.6 | -68.38 | -42.66 |
Selling, General & Admin | 33.38 | 37.55 | 46.46 | 38.46 | 38.02 | 24.32 |
Operating Expenses | 33.38 | 37.55 | 46.46 | 38.46 | 38.02 | 24.32 |
Operating Income | -107.2 | -133.92 | -166.62 | -116.06 | -106.4 | -66.98 |
Interest & Investment Income | 4.69 | 8 | 15.3 | 15.3 | - | - |
Earnings From Equity Investments | - | -9.16 | - | - | - | - |
Other Non Operating Income (Expenses) | 0.83 | 0.83 | 2.2 | -1.12 | 7.18 | -1.21 |
EBT Excluding Unusual Items | -101.68 | -134.25 | -149.11 | -101.88 | -99.22 | -68.19 |
Merger & Restructuring Charges | -2.28 | -2.28 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.13 | - |
Asset Writedown | - | -12.15 | - | - | - | - |
Other Unusual Items | - | - | - | - | - | 1.58 |
Pretax Income | -103.95 | -148.68 | -149.11 | -101.88 | -99.35 | -66.6 |
Income Tax Expense | -0.55 | -0.55 | -0.01 | 0.19 | 0.07 | 0.32 |
Net Income | -103.4 | -148.13 | -149.11 | -102.07 | -99.42 | -66.92 |
Net Income to Common | -103.4 | -148.13 | -149.11 | -102.07 | -99.42 | -66.92 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 96 | 93 | 90 | 74 | 61 | 32 |
Shares Outstanding (Diluted) | 96 | 93 | 90 | 74 | 61 | 32 |
Shares Change | 4.73% | 3.40% | 22.37% | 21.39% | 92.02% | 270.47% |
EPS (Basic) | -1.08 | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 |
EPS (Diluted) | -1.08 | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -95.75 | -112.35 | -143.08 | -104.9 | -97.42 | -34.64 |
Free Cash Flow Per Share | -1.00 | -1.20 | -1.58 | -1.42 | -1.60 | -1.09 |
Gross Margin | - | - | - | -225.07% | - | - |
Operating Margin | -1068.22% | -1200.09% | -1667.16% | -336.63% | -768.17% | -697.84% |
Profit Margin | -1030.42% | -1327.40% | -1491.94% | -296.05% | -717.79% | -697.26% |
Free Cash Flow Margin | -954.18% | -1006.82% | -1431.66% | -304.27% | -703.34% | -360.91% |
EBITDA | -104.61 | -130.27 | -162.69 | -112.53 | -104.78 | -66 |
D&A For EBITDA | 2.59 | 3.65 | 3.93 | 3.53 | 1.62 | 0.98 |
EBIT | -107.2 | -133.92 | -166.62 | -116.06 | -106.4 | -66.98 |